Previous close | 3.8200 |
Open | 3.8900 |
Bid | 3.7600 x 100 |
Ask | 3.9400 x 100 |
Day's range | 3.7710 - 3.9100 |
52-week range | 3.4400 - 6.2800 |
Volume | |
Avg. volume | 93,529 |
Market cap | 165.869M |
Beta (5Y monthly) | 1.45 |
PE ratio (TTM) | N/A |
EPS (TTM) | -0.0800 |
Earnings date | 07 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 6.88 |
HOLLISTON, Mass., April 29, 2024 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for the quarter ended March 31, 2024 before the market opens on May 7, 2024, and will hold a conference call to discuss the results at 8:00 a.m. Eastern Time. Participants who would like to join the call and ask a question must register here. Once registered, you will receive the dial-in numbers and a unique PIN number. Participants who would like to join the audio-onl
HOLLISTON, Mass., April 09, 2024 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced a labor force reduction to improve its operating cost structure and support its ongoing investments in growth. The Company expects to realize overall annual run rate savings of approximately $4 million beginning in the second quarter of 2024. The Company also expects second quarter restructuring-related charges of approximately $0.5 million. Jim Green, Harvard Bioscience Chairman and CEO,
It hasn't been the best quarter for Harvard Bioscience, Inc. ( NASDAQ:HBIO ) shareholders, since the share price has...